Abstract
AbstractOptimal noninvasive brain stimulation parameters for the treatment of negative symptoms of schizophrenia remain unclear. Here, we aimed to investigate the clinical and biological effects of intermittent theta burst transcranial magnetic stimulation (iTBS) in patients with treatment-resistant negative symptoms of schizophrenia (NCT00875498). In a randomized sham-controlled 2-arm study, 22 patients with schizophrenia and treatment-resistant negative symptoms received 20 sessions of either active (n = 12) or sham (n = 10) iTBS. Sessions were delivered twice a day on 10 consecutive working days. Negative symptom severity was assessed 5 times using the Scale for the Assessment of Negative Symptoms (SANS): before iTBS, after iTBS, and 1, 3, and 6 months after iTBS. As a secondary objective, we explored the acute effects of iTBS on functional connectivity of the left dorsolateral prefrontal cortex (DLPFC) using seed-based resting-state functional connectivity MRI (rsFC fMRI) images acquired before and after iTBS. Active iTBS over the left DLPFC significantly decreased negative symptoms severity compared to sham iTBS (F(3,60) = 3.321, p = 0.026). Post hoc analyses revealed that the difference between groups was significant 6 months after the end of stimulation sessions. Neuroimaging revealed an increase in rsFC between the left DLPFC and a brain region encompassing the right lateral occipital cortex and right angular gyrus and a right midbrain region that may encompass dopamine neuron cell bodies. Thus, iTBS over the left DLPFC can alleviate negative symptoms of schizophrenia. The effect might be driven by significant modulation of dopamine transmission.
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health
Reference51 articles.
1. McGurk, S. R., Mueser, K. T., Walling, D., Harvey, P. D. & Meltzer, H. Y. Cognitive functioning predicts outpatient service utilization in schizophrenia. Ment. Health Serv. Res. 6, 185–188 (2004).
2. Ayesa-Arriola, R. et al. Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. Psychopharmacology 227, 615–625 (2013).
3. Buoli, M. & Altamura, A. C. May non-antipsychotic drugs improve cognition of schizophrenia patients? Pharmacopsychiatry 48, 41–50 (2015).
4. National Collaborating Centre for Mental Health (UK). Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014. (National Institute for Health and Care Excellence (UK), 2014).
5. Wible, C. G. et al. Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatry Res. 108, 65–78 (2001).